The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
Hosted on MSN28d
Medicare Could Pay for Wegovy. Don’t Count On It.With less than two months left in office, the Biden administration said Tuesday it would seek to let Medicare pay for weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound ...
Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...
Senator Bernie Sanders (I-VT), for example, stated that “unless Medicare demands that Novo Nordisk and Eli Lilly substantially reduce the prices for these anti-obesity drugs, Medicare premiums ...
The prices were compared to 11 other countries{beacon} Health Care Health Care The Big Story Medicare negotiated prices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback